1. |
中华医学会血液学分会血栓与止血学组, 中国血友病协作组. 血友病诊断与治疗中国专家共识(2017年版). 中华血液学杂志, 2017, 38(5): 364-370.
|
2. |
Srivastava A, Santagostino E, Dougall A, et al. WFH guidelines for the management of hemophilia, 3rd edition. Haemophilia, 2020, 26(Suppl 6): 1-158.
|
3. |
Fischer K, van der Bom JG, Molho P, et al. Prophylactic versus on-demand treatment strategies for severe haemophilia: a comparison of costs and long-term outcome. Haemophilia, 2002, 8(6): 745-752.
|
4. |
Wu R, Luke KH. The benefit of low dose prophylaxis in the treatment of hemophilia: a focus on China. Expert Rev Hematol, 2017, 10(11): 995-1004.
|
5. |
Husereau D, Drummond M, Augustovski F, et al. Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. Clin Ther, 2022, 44(2): 158-168.
|
6. |
Husereau D, Drummond M, Augustovski F, et al. Consolidated health economic evaluation reporting standards (CHEERS) 2022 explanation and elaboration: a report of the ISPOR CHEERS Ⅱ good practices task force. Value Health, 2022, 25(1): 10-31.
|
7. |
Willke RJ, Pizzi LT. CHEERS to Updated guidelines for reporting health economic evaluations! Value Health, 2022, 25(1): 1-2.
|
8. |
Degeling K, Vu M, Koffijberg H, et al. Health economic models for metastatic colorectal cancer: a methodological review. Pharmacoeconomics, 2020, 38(7): 683-713.
|
9. |
Smith PS, Teutsch SM, Shaffer PA, et al. Episodic versus prophylactic infusions for hemophilia A: a cost-effectiveness analysis. J Pediatr, 1996, 129(3): 424-431.
|
10. |
Miners AH, Sabin CA, Tolley KH, et al. Cost-utility analysis of primary prophylaxis versus treatment on-demand for individuals with severe haemophilia. Pharmacoeconomics, 2002, 20(11): 759-774.
|
11. |
Risebrough N, Oh P, Blanchette V, et al. Cost-utility analysis of Canadian tailored prophylaxis, primary prophylaxis and on-demand therapy in young children with severe haemophilia A. Haemophilia, 2008, 14(4): 743-752.
|
12. |
Daliri AA, Haghparast H, Mamikhani J. Cost-effectiveness of prophylaxis against on-demand treatment in boys with severe hemophilia A in Iran. Int J Technol Assess Health Care, 2009, 25(4): 584-587.
|
13. |
Miners A. Revisiting the cost-effectiveness of primary prophylaxis with clotting factor for the treatment of severe haemophilia A. Haemophilia, 2009, 15(4): 881-887.
|
14. |
Colombo GL, Di Matteo S, Mancuso ME, et al. Cost-utility analysis of prophylaxis versus treatment on demand in severe hemophilia A. Clinicoecon Outcomes Res, 2011, 3: 55-61.
|
15. |
Farrugia A, Cassar J, Kimber MC, et al. Treatment for life for severe haemophilia A- A cost-utility model for prophylaxis vs. on-demand treatment. Haemophilia, 2013, 19(4): e228-e238.
|
16. |
Petrova G, Tachkov K, Georgieva S, et al. Humanistic and economic aspects of haemophilia treatment in Bulgaria. Comparison between two therapeutic approaches:prophylactic vs. on-demand treatment. Biotechnol Biotechnol Equip, 2014, 28(3): 576-582.
|
17. |
Castro JHE, Moreno VM, Mejia AE. Cost-utility analysis of primary prophylaxis, compared with on-demand treatment, for patients with severe hemophilia type a in colombia. Int J Technol Assess Health Care, 2016, 32(5): 337-347.
|
18. |
Iannazzo S, Cortesi PA, Crea R, et al. Cost-effectiveness analysis of pharmacokinetic-driven prophylaxis vs. standard prophylaxis in patients with severe haemophilia A. Blood Coagul Fibrinolysis, 2017, 28(6): 425-430.
|
19. |
Coppola A, D'Ausilio A, Aiello A, et al. Cost-effectiveness analysis of late prophylaxis vs. on-demand treatment for severe haemophilia A in Italy. Haemophilia, 2017, 23(3): 422-429.
|
20. |
Zahedi Z, Karimi M, Keshavarz K, et al. A cost-effectiveness analysis of the prophylaxis versus on-demand regimens in severe hemophilia A patients under 12 years old in southern Iran. Hematology, 2021, 26(1): 240-248.
|
21. |
张瑶, 马爱霞. 重组人凝血因子Ⅷ的小剂量预防方案对比按需治疗方案用于中国A型血友病患者的成本-效用分析. 中国药物经济学, 2021, 16: 62-66.
|
22. |
Henry N, Jovanović J, Schlueter M, et al. Cost-utility analysis of life-long prophylaxis with recombinant factor ⅧFc vs recombinant factor Ⅷ for the management of severe hemophilia A in Sweden. J Med Econ, 2018, 21(4): 318-325.
|
23. |
Bullement A, McMordie ST, Hatswell AJ, et al. Cost-effectiveness analysis of recombinant factor Ⅷ Fc-fusion protein (rFⅧFc) for the treatment of severe hemophilia A in Italy incorporating real-world dosing and joint health data. Pharmacoecon Open, 2020, 4(1): 133-142.
|
24. |
Lotfi F, Talebianpour H, Keshavarz K, et al. Cost-utility analysis of factor Ⅷ diet therapies prepared using blood plasma vs. recombinant technique for patients with hemophilia A. Daru, 2020, 28(1): 287-293.
|
25. |
Bullement A, Knowles ES, DasMahapatra P, et al. Cost-effectiveness analysis of rFⅧFc versus contemporary rFⅧ treatments for patients with severe hemophilia A without inhibitors in the United States. Pharmacoecon Open, 2021, 5(4): 625-633.
|
26. |
孙利华, 吴晶, 左根永, 等. 药物经济学第4版. 北京: 中国医药科技出版社, 2019: 124-125.
|
27. |
刘国恩, 胡善联, 吴久鸿, 等. 中国药物经济学评价指南2020: 中英双语版. 北京: 中国市场出版社, 2020: 5-55.
|
28. |
DF372. 我国首个国产重组凝血八因子产品获批. 北京: 中国证券报, 2021-07-24. Available at: https://finance.eastmoney.com/a/202107242012743283.html.
|
29. |
宣建伟, 孙巧. 中国罕见病药物经济学评估适用模型与支付阈值参考标准探讨. 国际药学研究杂志, 2019, 46(9): 659-665.
|